2 Jun 2016 16:34
2 June 2016
Amryt Pharma plc
Notice of Results for the nine months ended 31 December 2015
2 June 2016, London - Amryt Pharma plc ("Amryt" or the "Company") the specialty pharma company focused on best in class treatments for orphan diseases, will announce its results for the nine months ended 31 December 2015 on Thursday 9 June 2016.
Following the results announcement, the Company will host an analyst presentation and concurrent conference call at 9:00 am (UK) at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD. Please contact Ciara Martin at FTI Consulting +44 (0) 20 3727 1838 for details.
Amryt joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC raising £10m to accelerate the development of its lead product Episalvan.
-Ends-
For further information, please contact:
Amryt Pharma plc | C/o FTI Consulting |
Joe Wiley, CEO Rory Nealon, CFO/COO | |
Shore Capital | +44 (0) 20 7408 4090 |
Nomad and Joint Broker | |
Bidhi Bhoma, Edward Mansfield | |
Davy | +353 (1) 679 6363 |
ESM Adviser and Joint Broker | |
John Frain, Anthony Farrell | |
Stifel | +44 (0) 20 7710 7600 |
Joint Broker | |
Jonathan Senior, Ben Maddison | |
FTI Consulting | +44 (0) 20 3727 1000 |
Simon Conway, Brett Pollard |
About Amryt Pharma plc - see www.amrytpharma.com
Amryt Pharma is a specialty pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare or 'orphan' diseases. The Company is building a diversified portfolio of commercially attractive, best-in-class, propriety new drugs to help address some of these rare and debilitating illnesses for which there are currently no available treatments.
Amryt's lead product, Episalvan®, received marketing approval for the treatment of partial-thickness wounds from the European Commission in January 2016. Amryt intends to further develop Episalvan® as a new treatment for Epidermolysis Bullosa ("EB"), a rare and distressing genetic skin disorder affecting young children for which there is currently no treatment. Amryt is currently planning a phase III study of Episalvan® in EB, which has been granted US and EU orphan drug designation.
Amryt's earlier stage products are focused on developing novel, next generation somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases, where there is a high unmet medical need. These include acromegaly and Cushing's disease.
The Company joined AIM and Dublin's ESM in April 2016 following the reverse takeover of Fastnet Equity PLC.